| CD101 | IGSF2(immunoglobulin superfamily,member 2), V7, P126 |
| Molecule Type | Antigen Expression | Molecular Weight Min / Max |
| Non-lineage Restricted Molecule Type 1 glycoprotein | Granulocyte Monocyte Tumor Cell Blood Cell T Cell Spleen Dendritic Cell Small intestine Thymus Langerhans Cell Lung Peripheral blood Leukemia cell | 120 / 120 240 / 240 |
Expression | ||||||||||||||||
| CD101 is highly expressed on monocytes, granulocytes, mucosal T cells, cutaneous dendritic cells and on activated peripheral blood T cells. Expression is in some leukemic cells, CD4+ CD56+ blastic tumor cells as well as in Langerhans cells from histiocytois patients. Expression is weak on resting T and B and NK cells, absent from platelets and weak or absent from most hematopoietic cell lines. Northern blot analyses show CD101 mRNA to be present in PBLs, thymus, spleen, lung and small intestine, but not in other tissues. | ||||||||||||||||
Structure | ||||||||||||||||
| MOLECULAR FAMILY NAME: Belongs to the immunoglobulin supergene family. CD101 is a disulfide-linked homodimeric single-pass type-1 glycoprotein. It contains a 20 aa hydrophobic signal sequence, a 934 aa extracellular domain which contains 7 Ig-like V-type domains and has 7 potential N-linked glycosylation sites, a 25 aa tranmembrane domain and a 42 aa cytoplasmic domain and several phosphorylation consensus sites. MOLECULAR MASS
POST-TRANSCRIPTIONAL MODIFICATION: No information. POST-TRANSLATIONAL MODIFICATION The molecule is a glycoprotein with Asn-linked carbohydrates and the predicted structure has 7 potential Asn-linked sites. | ||||||||||||||||
Ligands | ||||||||||||||||
| LIGANDS AND MOLECULES ASSOCIATED FOR CD101: No information. | ||||||||||||||||
Function | ||||||||||||||||
| CD101 is thought to play a co-stimulatory role in TCR/CD3-mediated T cell activation. The anti-CD101 mAb V7.1 inhibits the proliferative response of CD4+ and CD8+ T cells in vitro to alloantigens and immobilized CD3 mAbs, but not to mitogenic lectins. Other CD101 mAbs are co-stimulatory for intraepithelial T lymphocytes when administered in vitro with suboptimal doses of CD3 mAb. Monoclonal antibodies against CD101 inhibit allogeneic T cell responses and co-stimulate T cell proliferation with suboptimal anti-CD3 activation. Triggering of CD101 on cutaneous dendritic cell was found to induce IL-10 secretion by the DCs which inhibit T cell proliferation in vitro. BIOCHEMICAL ACTIVITY: No information. DISEASE RELEVANCE AND FUNCTION OF CD101 IN INTACT ANIMAL CD101 is found on a subpopulation of T cells (CD101+, CD8+ and CD103+) with a possible role in preventing fetal rejection and inflammatory bowel disease in the gut mucosa. CD101 may also be a marker of CD4+ CD56+ leukemic tumor cells. | ||||||||||||||||
Comments | ||||||||||||||||
| MOLECULAR INTERACTIONS - PROTEINS AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD101: No information. SUBSTRATES: No information. ENZYMES WHICH MODIFY CD101: No information. ADDITIONAL INSIGHTS The physiological function is unknown. | ||||||||||||||||
Database accession numbers | ||||||||||||||||
Revised June 25, 2008
|
||||||||||||||||